BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Madsen BS, Havelund T, Krag A. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. Adv Ther 2013;30:659-70. [PMID: 23881723 DOI: 10.1007/s12325-013-0044-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Baffy G. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2018;63:563-76. [DOI: 10.1007/s10620-017-4903-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
2 Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol 2021;27:425-36. [PMID: 33317244 DOI: 10.3350/cmh.2020.0234] [Reference Citation Analysis]
3 Vipani A, Lindenmeyer CC, Sundaram V. Treatment of Severe Acute on Chronic Liver Failure: Management of Organ Failures, Investigational Therapeutics, and the Role of Liver Transplantation. J Clin Gastroenterol 2021;55:667-76. [PMID: 34028394 DOI: 10.1097/MCG.0000000000001568] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Madsen BS, Trebicka J, Thiele M, Israelsen M, Arumugan M, Havelund T, Krag A. Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial. Trials. 2018;19:143. [PMID: 29482588 DOI: 10.1186/s13063-018-2523-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
6 Scheiner B, Parada-Rodriguez D, Bucsics T, Schwabl P, Mandorfer M, Pfisterer N, Riedl F, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scand J Gastroenterol 2017;52:1008-15. [PMID: 28532189 DOI: 10.1080/00365521.2017.1329456] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2018;15:753-64. [DOI: 10.1038/s41575-018-0045-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
8 Rathi S, Dhiman RK. Hepatobiliary Quiz Answers-17 (2016). J Clin Exp Hepatol 2016;6:73-6. [PMID: 27194902 DOI: 10.1016/j.jceh.2016.03.005] [Reference Citation Analysis]
9 Mohamadkhani A. On the potential role of intestinal microbial community in hepatocarcinogenesis in chronic hepatitis B. Cancer Med. 2018;. [PMID: 29761927 DOI: 10.1002/cam4.1550] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
10 Meissner EG. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression? Clin Infect Dis 2018;67:878-80. [PMID: 29718134 DOI: 10.1093/cid/ciy208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Dirchwolf M, Marciano S, Martínez J, Ruf AE. Unresolved issues in the prophylaxis of bacterial infections in patients with cirrhosis. World J Hepatol 2018; 10(12): 892-897 [PMID: 30631393 DOI: 10.4254/wjh.v10.i12.892] [Reference Citation Analysis]
12 Cullaro G, Sharma R, Trebicka J, Cárdenas A, Verna EC. Precipitants of Acute-on-Chronic Liver Failure: An Opportunity for Preventative Measures to Improve Outcomes. Liver Transpl 2020;26:283-93. [PMID: 31714011 DOI: 10.1002/lt.25678] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
13 Tao X, Wang N, Qin W. Gut Microbiota and Hepatocellular Carcinoma. Gastrointest Tumors. 2015;2:33-40. [PMID: 26673641 DOI: 10.1159/000380895] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
14 Bunchorntavakul C, Reddy KR. Pharmacologic Management of Portal Hypertension. Clin Liver Dis 2019;23:713-36. [PMID: 31563219 DOI: 10.1016/j.cld.2019.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Fatima N, Akhtar T, Sheikh N. Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2017;2017:6238106. [PMID: 28573132 DOI: 10.1155/2017/6238106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
16 Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017;14:527-39. [PMID: 28676707 DOI: 10.1038/nrgastro.2017.72] [Cited by in Crossref: 176] [Cited by in F6Publishing: 168] [Article Influence: 35.2] [Reference Citation Analysis]
17 Egerod Israelsen M, Gluud LL, Krag A. Acute kidney injury and hepatorenal syndrome in cirrhosis. J Gastroenterol Hepatol 2015;30:236-43. [PMID: 25160511 DOI: 10.1111/jgh.12709] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
18 Lee PC, Chen YJ, Chou YC, Lee KC, Chen PH, Kao WY, Huang YH, Huo TI, Lin HC, Hou MC, Lee FY, Wu JC, Su CW. Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2020;32:365-72. [PMID: 31688303 DOI: 10.1097/MEG.0000000000001511] [Reference Citation Analysis]
19 Mookerjee RP, Pavesi M, Thomsen KL, Mehta G, Macnaughtan J, Bendtsen F, Coenraad M, Sperl J, Gines P, Moreau R, Arroyo V, Jalan R; CANONIC Study Investigators of the EASL-CLIF Consortium. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol. 2016;64:574-582. [PMID: 26519600 DOI: 10.1016/j.jhep.2015.10.018] [Cited by in Crossref: 120] [Cited by in F6Publishing: 89] [Article Influence: 17.1] [Reference Citation Analysis]